DS
BOLT icon

DRW Securities’s Bolt Biotherapeutics BOLT Stock Holding History

DRW Securities’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,322
Closed -$65.6K – 1269
2025
Q3 		$65.6K Buy
+12,322
New +$68.3K ﹤0.01% 1217

Other funds holding BOLT

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DRW Securities's BOLT Position: Q4 2025 in Review

DRW Securities sold out of Bolt Biotherapeutics (BOLT) in Q4 2025, closing a stake of 12,322 shares — an estimated $65.6K sold.

DRW Securities first reported a position in BOLT in Q3 2025 and held it in 1 quarter. The position peaked at $65.6K in Q3 2025. 21 funds tracked by Wall St. Rank hold BOLT as of Q4 2025.

  • DRW Securities reported no remaining Bolt Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • DRW Securities sold 12,322 Bolt Biotherapeutics shares in Q4 2025, an estimated $65.6K.
  • DRW Securities first reported a position in Bolt Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • DRW Securities's Bolt Biotherapeutics position peaked at $65.6K in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.